Tech-Biotech Convergence, Growth, and Global Lessons, Vik Bajaj, Co-founder and CEO

The convergence of technology and biotechnology is fundamentally transforming drug development and healthcare delivery by leveraging large-scale datasets and machine learning to personalize patient care. Vik Bajaj, Managing Director of Foresight Capital Management and CEO of Foresight Labs, highlights how data-driven approaches—modeled after tech industry practices—enable faster, more precise clinical trials and diagnostic breakthroughs, such as early cancer detection. While the current financing landscape demands rigorous focus on tangible product value and clinical utility, significant capital remains available for transformational, platform-based innovations. Moving forward, the integration of routine clinical data and the adoption of cross-disciplinary research models will be essential to overcoming traditional, decade-long development cycles. By emulating the data-rich infrastructure of international systems like the UK’s single-payer model, the U.S. can build a distributed framework that accelerates biological discovery and improves long-term patient outcomes.